Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$33.01

From 52W high+0.00%

Volume489942.00

Market cap$4.15B

P/E (TTM)149.7x

P/S (TTM)9.0x

Div yield—

Key dataNov 4, 2026

Open

$33.01

From 52W high

+0.00%

Volume

489942.00

Market cap

$4.15B

ValuationView details →

P/E (Fwd)

38.5x

EV/EBITDA

92.8x

P/E (TTM)

149.7x

RSI (14)

65.3

MomentumView details →

1D Return

+3.30%

YTD Return

+11.57%

SummaryUpdated Jun 1, 2026

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage biopharmaceutical company founded in 2016 and headquartered in Westlake Village, California. The company went public in January 2020 and focuses on developing and commercializing innovative treatments for dermatological diseases. Arcutis has successfully transitioned from a clinical-stage company to a commercial enterprise, with its flagship product ZORYVE generating significant revenue growth since its initial launch for plaque psoriasis in 2022.

Ask drillr about Arcutis Biotherapeutics, Inc. →

ValuationView details →

P/E (Fwd)

38.5x

P/E (TTM)

149.7x

EV/EBITDA

92.8x

EV/Sales

8.7x

P/S (TTM)

9.0x

P/B (TTM)

18.8x

ProfitabilityView details →

Gross Margin

91.14%

Net Margin

6.15%

EBITDA Margin

9.36%

ROE (TTM)

12.93%

ROA (TTM)

5.84%

Asset Turnover

0.98x

GrowthView details →

Revenue YoY

+76.11%

EPS YoY

+129.47%

FCF YoY

+154.89%

Revenue CAGR 3Y

+367.27%

EPS CAGR 3Y

+88.79%

EBITDA YoY

+163.38%

MomentumView details →

1D Return

+3.30%

YTD Return

+11.57%

1Y Return

+32.89%

RSI (14)

65.3

vs 50D SMA

+19.64%

vs 200D SMA

+27.88%

Capital & dividendView details →

Debt/Equity

0.52x

Current Ratio

2.92x

Quick Ratio

2.67x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.11

EPS Surprise

99.71%

Beats (12Q)

8/12

Next Q EPS Est

$0.25

Avg Surprise (4Q)

27.71%

Rev Surprise

9.26%

Financials snapshotView financials →

Revenue (TTM)

463.98M

Net Income (TTM)

28.52M

Op. CF (TTM)

39.31M

Next earningsNov 4, 2026 →

Latest newsMore news →

Arcutis Biotherapeutics appointed Robert Scott as a member of its board and Nominating and Corporate Governance Committee.7d ago

Arcutis announced that it will report its third-quarter 2026 financial results and provide a business update after U.S. financial markets close on November 4, 2026.14d ago

Similar companies

Veracyte, Inc.VCYT Ocumension Therapeutics01477.HK Edgewise Therapeutics, Inc.EWTX Adaptive Biotechnologies CorporationADPT Abbisko Cayman Limited02256.HK 华恒生物688639.SH Find similar companies →

Latest newsMore news →

Arcutis Biotherapeutics appointed Robert Scott as a member of its board and Nominating and Corporate Governance Committee.7d ago Arcutis announced that it will report its third-quarter 2026 financial results and provide a business update after U.S. financial markets close on November 4, 2026.14d ago